Look on the "air side" in pneumonia

Critical Care Medicine

Volumn 37, Issue 2, 2009, Pages 774-775

  Heslet, Lars ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Alveolarhemostasis activation; Diffuse alveolar damage; Gram negative antigen; Gram positive antigen; Inhaled activated protein C; Pneumonia; Pulmonary deposition

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBIN; BACTERIAL ANTIGEN; DROTRECOGIN; FIBRINOLYTIC AGENT; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE LUNG INJURY; ANTIBIOTIC THERAPY; BACTERIAL CELL WALL; BLEEDING; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; EDITORIAL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMOSTASIS; HOSPITAL INFECTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LUNG GAS EXCHANGE; MORTALITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; SEPSIS;

ACUTE LUNG INJURY; ANTIGENS; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; HUMANS; PNEUMONIA; PROTEIN C INHIBITOR; RESPIRATORY THERAPY; SERINE PROTEINASE INHIBITORS;

EID: 67650401363     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318194cf47     Document Type: Editorial

References (17)

1. Gunther A, Mosavi P, Heinemann S, et al: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-446
2. Ware LB: Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med 2006; 27:337-349
3. Schultz MJ, Haitsma JJ, Zhang H, et al: Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia: A review. Crit Care Med 2006; 34: 871-877
4. Isakow W, Kollef MH: Preventing ventilator-associated pneumonia: An evidence-based approach of modifiable risk factors. Semin Respir Crit Care Med 2006; 27:5-17
5. Hoogerwerf JJ, de Vos AF, Levi M, et al: Activation of coagulation and inhibition of fibrinolysis in the human lung on bronchial instillation of lipoteichoic acid and lipopolysaccharide. Crit Care Med 2009; 37:619-625
6. Gando S, Kameue T, Matsuda N, et al: Imbalance between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res 2003; 109: 119-124
7. Ware LB, Fang X, Matthay MA: Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285:L514-L521
8. van der Poll T, Levi M, Nick JA, et al: Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005; 171:1125-1128
9. Welty-Wolf KE, Carraway MS, Miller DL, et al: Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001; 164:1988-1996
10. Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 2003; 290:238-247
11. LifeSciencesWorld: Chiron begins phase III trial for tifacogin. May 18, 2004. Available at: www.lifesciencesworld.com/rss/tifacogin/ news. Accessed October 12, 2006
12. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recom-binant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709
13. Liu KD, Levitt J, Zhuo H, et al: Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178:618-623
14. Marti-Carvajal A, Salanti G, Cardona AF: Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2008; (1):CD004388
15. Levi M: Activated protein C in sepsis: A critical review. Curr Opin Hematol 2008; 15: 481-486
16. Heslet L, Andersen JS, Sengeløv H, et al: Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome. Targets Ther 2007; 1:1-8
17. Slofstra SH, Groot AP, Maris NA, et al: Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol 2006; 149: 740-746